Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Immunohistochemical evaluation of a new epithelial antigen, BER-EP4 in ovarian cancer: a propos of 62 cases
G. Capobianco1, V. Marras2, G. Battista Meloni3, S. Dessole1, N. Ashqar1, C. Cherchi1, F. Dessole1, P. L. Cherchi1,*
1 Gynecologic and Obstetric Clinic, 2Institute of Pathology, 3Institute of Radiology, University of Sassari, Sassari (Italy)
Eur. J. Gynaecol. Oncol. 2012, 33(1), 90–92;
Published: 10 February 2012
Objective: To assess the immunohistochemical expression of BerEP4, a new epithelial antigen in ovarian cancer. Methods:We studied 62 cases of ovarian cancer in which BerEP4, CEA and CA-125 were investigated by an immunohistochemical method. We evaluated the correlations among immunohistochemical positivity and the grading, histotype and stage of disease. Results: BerEP4 was positive in 45 out of 62 cases (72.58%), CA-125 in 36 out of 62 cases (58.06%) and CEA in ten out of 62 cases (16.13%). BerEP4 was present both in serous and in mucinous tumors (80.96% vs 80.77%). CA-125 was mainly expressed in serous vs mucinous tumors (66.67% vs 57.69%). CEA was more prevalent in mucinous vs serous tumors. Ber-EP4 was mainly expressed in G1 (75%) and G2 (77.27%). CA-125 was more present in G1 and G3 (both 62.50%) than G2 (50%), whereas CEA showed positivity in G1: 12.50%, G2: 22.73% and G3: 12.50%. There were no differences among the three antigens studied with regard to clinical stage. Conclusions: In our study Ber-EP4 was positive in 45 out of 62 cases (72.58%) of primary epithelial ovarian cancers. The presence of this antigen seemed to be related to the histotype and grading but not to clinical stage.